Improvements in exercise ability and quality of life (QoL) after treatment are quite significant for patients with HF, especially for those with HFpEF, as treatments to improve prognosis are relatively scarce.
← all excerpts
Effects of empagliflozin on cardiac structure, function and biomarkers in patients with heart failure with preserved ejection fraction: study protocol for a randomised, placebo-controlled prospective trial.
1
—
—